| Jackie L Hinds, MD | |
|
651 Dunlop Ln., Gateway Med Center, Clarksville, TN 37040-5015 | |
| (931) 502-1370 | |
| Not Available |
| Full Name | Jackie L Hinds |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 24 Years |
| Location | 651 Dunlop Ln., Clarksville, Tennessee |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346277324 | NPI | - | NPPES |
| 00A857130 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | A85713 (California) | Secondary |
| 207P00000X | Emergency Medicine | 44991 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Round Rock Medical Center | Round rock, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Round Rock Emergency Physicians Pllc | 0648524306 | 3 |
| Longhorn Emergency Medical Associates Pa | 4486971041 | 96 |
| Brushy Creek Emergency Physicians | 8729483854 | 11 |
News Archive
Covidien, a leading global provider of healthcare products, announced the results of an analysis that will be presented at the American College of Rheumatology's Annual Scientific Meeting. A pooled analysis of safety data suggests that patients with knee osteoarthritis (OA) receiving the topical PENNSAID® (diclofenac sodium topical solution) 1.5% w/w had significantly fewer gastrointestinal (GI)-related adverse events than those receiving an oral non-steroidal anti-inflammatory drug (NSAID).
Despite ongoing public health efforts, E. coli outbreaks continue to infiltrate the food supply, annually causing significant sickness and death throughout the world. But the research community is gaining ground. In a major finding, published today in the scientific journal Nature, researchers from the La Jolla Institute for Allergy & Immunology have discovered a molecule's previously unknown role in fighting off E. coli and other bacterial infections, a discovery that could lead to new ways to protect people from these dangerous microorganisms.
ArQule, Inc. today announced the commencement of patient dosing in a Phase 1 clinical trial with ARQ 736, a small molecule inhibitor of the RAF kinases.
Thousands of sequences that control genes are active in the developing human limb and may have driven the evolution of the human hand and foot, a comparative genomics study led by Yale School of Medicine researchers has found.
Results from a large, prospective clinical trial add to mounting evidence that adolescent and young adult patients-aged 16 to 39 with acute lymphoblastic leukemia (ALL)-tend to fare better when treated with high-intensity pediatric protocols than previous patients who were treated with standard adult regimens.
› Verified 7 days ago
| Entity Name | Longhorn Emergency Medical Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649669672 PECOS PAC ID: 4486971041 Enrollment ID: O20150320000152 |
News Archive
Covidien, a leading global provider of healthcare products, announced the results of an analysis that will be presented at the American College of Rheumatology's Annual Scientific Meeting. A pooled analysis of safety data suggests that patients with knee osteoarthritis (OA) receiving the topical PENNSAID® (diclofenac sodium topical solution) 1.5% w/w had significantly fewer gastrointestinal (GI)-related adverse events than those receiving an oral non-steroidal anti-inflammatory drug (NSAID).
Despite ongoing public health efforts, E. coli outbreaks continue to infiltrate the food supply, annually causing significant sickness and death throughout the world. But the research community is gaining ground. In a major finding, published today in the scientific journal Nature, researchers from the La Jolla Institute for Allergy & Immunology have discovered a molecule's previously unknown role in fighting off E. coli and other bacterial infections, a discovery that could lead to new ways to protect people from these dangerous microorganisms.
ArQule, Inc. today announced the commencement of patient dosing in a Phase 1 clinical trial with ARQ 736, a small molecule inhibitor of the RAF kinases.
Thousands of sequences that control genes are active in the developing human limb and may have driven the evolution of the human hand and foot, a comparative genomics study led by Yale School of Medicine researchers has found.
Results from a large, prospective clinical trial add to mounting evidence that adolescent and young adult patients-aged 16 to 39 with acute lymphoblastic leukemia (ALL)-tend to fare better when treated with high-intensity pediatric protocols than previous patients who were treated with standard adult regimens.
› Verified 7 days ago
| Entity Name | Lakeline Emergency Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316426505 PECOS PAC ID: 7214281492 Enrollment ID: O20181107002405 |
News Archive
Covidien, a leading global provider of healthcare products, announced the results of an analysis that will be presented at the American College of Rheumatology's Annual Scientific Meeting. A pooled analysis of safety data suggests that patients with knee osteoarthritis (OA) receiving the topical PENNSAID® (diclofenac sodium topical solution) 1.5% w/w had significantly fewer gastrointestinal (GI)-related adverse events than those receiving an oral non-steroidal anti-inflammatory drug (NSAID).
Despite ongoing public health efforts, E. coli outbreaks continue to infiltrate the food supply, annually causing significant sickness and death throughout the world. But the research community is gaining ground. In a major finding, published today in the scientific journal Nature, researchers from the La Jolla Institute for Allergy & Immunology have discovered a molecule's previously unknown role in fighting off E. coli and other bacterial infections, a discovery that could lead to new ways to protect people from these dangerous microorganisms.
ArQule, Inc. today announced the commencement of patient dosing in a Phase 1 clinical trial with ARQ 736, a small molecule inhibitor of the RAF kinases.
Thousands of sequences that control genes are active in the developing human limb and may have driven the evolution of the human hand and foot, a comparative genomics study led by Yale School of Medicine researchers has found.
Results from a large, prospective clinical trial add to mounting evidence that adolescent and young adult patients-aged 16 to 39 with acute lymphoblastic leukemia (ALL)-tend to fare better when treated with high-intensity pediatric protocols than previous patients who were treated with standard adult regimens.
› Verified 7 days ago
| Entity Name | Round Rock Emergency Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902264963 PECOS PAC ID: 0648524306 Enrollment ID: O20181119001606 |
News Archive
Covidien, a leading global provider of healthcare products, announced the results of an analysis that will be presented at the American College of Rheumatology's Annual Scientific Meeting. A pooled analysis of safety data suggests that patients with knee osteoarthritis (OA) receiving the topical PENNSAID® (diclofenac sodium topical solution) 1.5% w/w had significantly fewer gastrointestinal (GI)-related adverse events than those receiving an oral non-steroidal anti-inflammatory drug (NSAID).
Despite ongoing public health efforts, E. coli outbreaks continue to infiltrate the food supply, annually causing significant sickness and death throughout the world. But the research community is gaining ground. In a major finding, published today in the scientific journal Nature, researchers from the La Jolla Institute for Allergy & Immunology have discovered a molecule's previously unknown role in fighting off E. coli and other bacterial infections, a discovery that could lead to new ways to protect people from these dangerous microorganisms.
ArQule, Inc. today announced the commencement of patient dosing in a Phase 1 clinical trial with ARQ 736, a small molecule inhibitor of the RAF kinases.
Thousands of sequences that control genes are active in the developing human limb and may have driven the evolution of the human hand and foot, a comparative genomics study led by Yale School of Medicine researchers has found.
Results from a large, prospective clinical trial add to mounting evidence that adolescent and young adult patients-aged 16 to 39 with acute lymphoblastic leukemia (ALL)-tend to fare better when treated with high-intensity pediatric protocols than previous patients who were treated with standard adult regimens.
› Verified 7 days ago
| Entity Name | Lake Travis Emergency Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851803688 PECOS PAC ID: 7315291929 Enrollment ID: O20181120000263 |
News Archive
Covidien, a leading global provider of healthcare products, announced the results of an analysis that will be presented at the American College of Rheumatology's Annual Scientific Meeting. A pooled analysis of safety data suggests that patients with knee osteoarthritis (OA) receiving the topical PENNSAID® (diclofenac sodium topical solution) 1.5% w/w had significantly fewer gastrointestinal (GI)-related adverse events than those receiving an oral non-steroidal anti-inflammatory drug (NSAID).
Despite ongoing public health efforts, E. coli outbreaks continue to infiltrate the food supply, annually causing significant sickness and death throughout the world. But the research community is gaining ground. In a major finding, published today in the scientific journal Nature, researchers from the La Jolla Institute for Allergy & Immunology have discovered a molecule's previously unknown role in fighting off E. coli and other bacterial infections, a discovery that could lead to new ways to protect people from these dangerous microorganisms.
ArQule, Inc. today announced the commencement of patient dosing in a Phase 1 clinical trial with ARQ 736, a small molecule inhibitor of the RAF kinases.
Thousands of sequences that control genes are active in the developing human limb and may have driven the evolution of the human hand and foot, a comparative genomics study led by Yale School of Medicine researchers has found.
Results from a large, prospective clinical trial add to mounting evidence that adolescent and young adult patients-aged 16 to 39 with acute lymphoblastic leukemia (ALL)-tend to fare better when treated with high-intensity pediatric protocols than previous patients who were treated with standard adult regimens.
› Verified 7 days ago
| Entity Name | Georgetown Emergency Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679085401 PECOS PAC ID: 9335483676 Enrollment ID: O20181128000055 |
News Archive
Covidien, a leading global provider of healthcare products, announced the results of an analysis that will be presented at the American College of Rheumatology's Annual Scientific Meeting. A pooled analysis of safety data suggests that patients with knee osteoarthritis (OA) receiving the topical PENNSAID® (diclofenac sodium topical solution) 1.5% w/w had significantly fewer gastrointestinal (GI)-related adverse events than those receiving an oral non-steroidal anti-inflammatory drug (NSAID).
Despite ongoing public health efforts, E. coli outbreaks continue to infiltrate the food supply, annually causing significant sickness and death throughout the world. But the research community is gaining ground. In a major finding, published today in the scientific journal Nature, researchers from the La Jolla Institute for Allergy & Immunology have discovered a molecule's previously unknown role in fighting off E. coli and other bacterial infections, a discovery that could lead to new ways to protect people from these dangerous microorganisms.
ArQule, Inc. today announced the commencement of patient dosing in a Phase 1 clinical trial with ARQ 736, a small molecule inhibitor of the RAF kinases.
Thousands of sequences that control genes are active in the developing human limb and may have driven the evolution of the human hand and foot, a comparative genomics study led by Yale School of Medicine researchers has found.
Results from a large, prospective clinical trial add to mounting evidence that adolescent and young adult patients-aged 16 to 39 with acute lymphoblastic leukemia (ALL)-tend to fare better when treated with high-intensity pediatric protocols than previous patients who were treated with standard adult regimens.
› Verified 7 days ago
| Entity Name | Brushy Creek Emergency Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235773151 PECOS PAC ID: 8729483854 Enrollment ID: O20210826003061 |
News Archive
Covidien, a leading global provider of healthcare products, announced the results of an analysis that will be presented at the American College of Rheumatology's Annual Scientific Meeting. A pooled analysis of safety data suggests that patients with knee osteoarthritis (OA) receiving the topical PENNSAID® (diclofenac sodium topical solution) 1.5% w/w had significantly fewer gastrointestinal (GI)-related adverse events than those receiving an oral non-steroidal anti-inflammatory drug (NSAID).
Despite ongoing public health efforts, E. coli outbreaks continue to infiltrate the food supply, annually causing significant sickness and death throughout the world. But the research community is gaining ground. In a major finding, published today in the scientific journal Nature, researchers from the La Jolla Institute for Allergy & Immunology have discovered a molecule's previously unknown role in fighting off E. coli and other bacterial infections, a discovery that could lead to new ways to protect people from these dangerous microorganisms.
ArQule, Inc. today announced the commencement of patient dosing in a Phase 1 clinical trial with ARQ 736, a small molecule inhibitor of the RAF kinases.
Thousands of sequences that control genes are active in the developing human limb and may have driven the evolution of the human hand and foot, a comparative genomics study led by Yale School of Medicine researchers has found.
Results from a large, prospective clinical trial add to mounting evidence that adolescent and young adult patients-aged 16 to 39 with acute lymphoblastic leukemia (ALL)-tend to fare better when treated with high-intensity pediatric protocols than previous patients who were treated with standard adult regimens.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jackie L Hinds, MD 2020 21st Ave S, Suite 201, Esn, Nashville, TN 37212 Ph: (615) 269-0652 | Jackie L Hinds, MD 651 Dunlop Ln., Gateway Med Center, Clarksville, TN 37040-5015 Ph: (931) 502-1370 |
News Archive
Covidien, a leading global provider of healthcare products, announced the results of an analysis that will be presented at the American College of Rheumatology's Annual Scientific Meeting. A pooled analysis of safety data suggests that patients with knee osteoarthritis (OA) receiving the topical PENNSAID® (diclofenac sodium topical solution) 1.5% w/w had significantly fewer gastrointestinal (GI)-related adverse events than those receiving an oral non-steroidal anti-inflammatory drug (NSAID).
Despite ongoing public health efforts, E. coli outbreaks continue to infiltrate the food supply, annually causing significant sickness and death throughout the world. But the research community is gaining ground. In a major finding, published today in the scientific journal Nature, researchers from the La Jolla Institute for Allergy & Immunology have discovered a molecule's previously unknown role in fighting off E. coli and other bacterial infections, a discovery that could lead to new ways to protect people from these dangerous microorganisms.
ArQule, Inc. today announced the commencement of patient dosing in a Phase 1 clinical trial with ARQ 736, a small molecule inhibitor of the RAF kinases.
Thousands of sequences that control genes are active in the developing human limb and may have driven the evolution of the human hand and foot, a comparative genomics study led by Yale School of Medicine researchers has found.
Results from a large, prospective clinical trial add to mounting evidence that adolescent and young adult patients-aged 16 to 39 with acute lymphoblastic leukemia (ALL)-tend to fare better when treated with high-intensity pediatric protocols than previous patients who were treated with standard adult regimens.
› Verified 7 days ago
John D Shields, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1771 Madison St, Clarksville, TN 37043 Phone: 931-552-6622 | |
Dr. Malcolm A Steele, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 651 Dunlop Ln, Clarksville, TN 37040 Phone: 931-502-1370 | |
Manickam Krishnamurthy, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 651 Dunlop Ln, Clarksville, TN 37040 Phone: 931-502-1370 | |
Mark A Muiznieks, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 651 Dunlop Lane Clarksville, Clarksville, TN 37040 Phone: 931-502-1370 | |
Dr. Russell Paul Landry Iii, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 651 Dunlop Lane, Clarksville, TN 37040 Phone: 713-430-6095 | |
Dr. Timothy L Obernuefemann, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2320 Wilma Rudolph Blvd, Clarksville, TN 37040 Phone: 931-645-1564 Fax: 931-645-3842 | |
Dr. James Willis Hickerson Jr., MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 651 Dunlop Ln, Clarksville, TN 37040 Phone: 931-502-1370 |